BPC-157 + TB-500 Blend: Dubai Research Vial COA & Purity
The BPC-157 + TB-500 blend — often searched unhyphenated as "bpc 157 tb 500" and nicknamed the "wolverine peptide" stack — puts two tissue-repair peptides in a single co-formulated vial. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.
Update History ▾
Research-use-only framing applied throughout in line with Remy editorial standards.
The BPC-157 + TB-500 blend pairs two distinct tissue-repair peptides in one vial, so the sourcing question really comes down to a COA that verifies both components — and an honest read of an evidence base that has no human combination data behind it. Remy Peptides currently lists the BPC-157 + TB-500 blend vial as In stock, supplied as a single lyophilized vial holding 5 mg BPC-157 + 5 mg TB-500 (10 mg total peptide, fixed 1:1 mass ratio), with current AED tiers starting around AED 500 in the product catalog. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.
Verifying the BPC-157 + TB-500 blend
This pair goes by a tangle of names, which is the first thing to pin down before sourcing it. You will see BPC-157 written in full as Body Protection Compound, and TB-500 is the marketed name for a synthetic Thymosin Beta-4 fragment — not full-length Tβ4 itself. Put together, the two are commonly searched unhyphenated as "bpc 157 tb 500", written as the "bpc-157 tb-500 blend", and nicknamed the "wolverine peptide" stack, and researchers in the UAE often add a location — "bpc tb 500 dubai" — when they are looking for a verified local source. Whatever spelling brings you here, the vial is the same co-formulated 5mg/5mg item, and the checks below apply equally.
For current product facts, start with the BPC-157 + TB-500 blend vial. The component pharmacology lives in the dedicated guides linked further down.
Blend Identity: One Vial, Two Peptides
The blend is a single lyophilized research vial containing 5 mg BPC-157 co-formulated with 5 mg of the TB-500 synthetic Thymosin Beta-4 fragment, for 10 mg total peptide content per vial. The two compounds are co-lyophilized rather than packaged separately, which fixes the reconstitution ratio at 1:1 by mass and removes the per-compound dilution step.[1]
BPC-157 is a 15-amino-acid pentadecapeptide (CAS 137525-51-0, MW 1419.55 g/mol) studied in preclinical tissue-repair models, and TB-500 is the marketed name for a synthetic short fragment modelled on the active region of Thymosin Beta-4 (Tβ4 reference CAS 77591-33-4).[1][2] The published rationale for putting them in one vial is mechanistic complementarity, not demonstrated synergy: the two compounds act on distinct, non-overlapping biology, which is why investigators sometimes co-administer them in animal-model repair work. The deep per-compound walk-throughs live in the component guides linked below; this page intentionally does not repeat them.
One word matters for compliance: "synergy" is a specific pharmacological claim that requires combination data showing the joint effect exceeds the additive sum of the two single-agent effects. No such combination dataset has been published for BPC-157 + TB-500, so the honest description of the stack is complementary co-administration. The fuller treatment of why that distinction matters is in the BPC-157 + TB-500 dual-peptide mechanism review.
Evidence Map and Translation Limits
Both compounds have a real preclinical record and a thin individual human record, but the combination evidence base is, in human terms, empty: a PubMed and ClinicalTrials.gov search at the time of writing returns no peer-reviewed human combination cohort or registered trial of BPC-157 with TB-500.[3] The table below maps where the blend sits, and what each layer means when you are sourcing it.
| Research layer | What the literature supports | What it means for sourcing |
|---|---|---|
| Blend identity | Two distinct, separately indexed compounds co-lyophilized at a fixed 5 mg + 5 mg (1:1) mass ratio in one vial. | A listing and COA should name both components and the total fill — that is how you confirm you are getting a true blend, not one peptide relabelled. |
| Per-compound mechanism | BPC-157 carries the nitric-oxide / VEGF-eNOS / FAK-paxillin preclinical record; the Tβ4 fragment carries the actin-sequestration / cell-migration record. Pathways are complementary, not overlapping. | Explains why the two are co-administered — read it as complementary co-administration, not as proven synergy. |
| Combination evidence | No peer-reviewed human combination trial and no registered Phase 2/3 trial of the pair exist; public combination material is preclinical, anecdotal, or bench characterisation. | Treat the combination as untested in humans; nothing supports a "more effective than separate vials" claim. |
| Sourcing in the UAE | Local researchers need both peptides confirmed, a COA covering each component, cold-chain handling, and a verifiable supplier route. | Confirm both peptides, the 5 mg + 5 mg fill, AED tier, stock, and a lot-specific COA on the product page. |
COA & Purity Verification for a Two-Peptide Vial
Verifying a blend is not the same as verifying a single-compound vial. A one-peptide Certificate of Analysis confirms one identity and one HPLC purity figure; a blend COA has to account for both peptides and the fill ratio. For a BPC-157 + TB-500 vial, a research buyer should look for:
- Separate identity confirmation for each peptide. Mass-spectrometry confirmation of BPC-157 (CAS 137525-51-0) and the TB-500 synthetic fragment (Tβ4 reference CAS 77591-33-4) as two distinct species, not a single combined mass.
- Per-peptide HPLC purity. An HPLC trace that resolves both peptides, with a purity figure attributable to each component rather than one aggregate number that could hide an under-filled or contaminated component.
- The 5 mg + 5 mg fill. Documentation that the vial holds the stated 1:1 mass ratio, since the whole point of the blend format is a fixed ratio.
- Batch-specific, not generic. COA language tied to a lot number, with the document available before purchase or on request, rather than a stock marketing figure reused across batches.
Remy Peptides centralizes that workflow through the product page, the COA library, and contact verification. Where a public batch file is not yet posted, the lot-specific HPLC documentation can be requested before dispatch. For the wider methodology of reading a peptide COA, see the peptide COA & HPLC purity guide.
Dubai/UAE Product Documentation
The live product page is the source of truth for price and stock. The table below mirrors the stable catalog facts for the blend — always check the current listing before ordering or a restock check.
| Field | Current Remy Peptides listing |
|---|---|
| Product page | BPC-157 + TB-500 blend vial |
| Format | 5 mg BPC-157 + 5 mg TB-500 · Lyophilized research vial (10 mg total, 1:1 mass ratio) |
| Stock status | In stock |
| AED price tier | From AED 500 — check the product page for current pack tiers |
| COA route | Check the product page and COA library; request lot-specific HPLC documentation covering both peptides when a public batch file is not yet posted. |
| Handling | 2-8°C cold-chain; same-day Dubai dispatch before 4 PM, next-day tracked UAE-wide delivery. |
| Use restriction | For in-vitro laboratory research only. Not for human or veterinary use. |
The standard reconstitution math for the 10 mg total fill is documented in the reconstitution calculator. In a research context, "bpc-157 tb-500 dosage" maps only to this reconstitution and working-concentration math, not to any administration protocol. Because both peptides share the vial at 5 mg each, the volume calculation is the same as for a single-compound research vial of 10 mg total mass, with the working concentration split 1:1 between the two peptides by mass.
Blend or Separate Vials? See the Component Guides
Rather than repeat each compound's pharmacology here, the deeper detail is split across three existing pages. Use this short map to pick the right next read:
- For the BPC-157 component — its identity, COA tier, and Dubai routing — see the BPC-157 Dubai COA research vial guide.
- For the TB-500 component — including the important distinction between the synthetic fragment and full-length Thymosin Beta-4 — see the TB-500 Dubai research vial guide.
- For the combination question itself — why the two are stacked, the human-combination evidence gap, and the FDA compounding backdrop — see the BPC-157 + TB-500 dual-peptide mechanism review.
The practical decision: investigators running a fixed 1:1 mass ratio in a co-administration protocol typically prefer the blend vial; investigators who need independent titration of either compound, different per-compound reconstitution volumes, or per-compound COA tracking typically prefer the separate BPC-157 10mg vial and TB-500 10mg vial, which ship from the same Dubai stock under the same cold-chain handling.
What This Page Does Not Claim
The research record helps define both compounds, but it does not turn a co-formulated RUO vial into a clinical product — and the absence of any combination cohort makes that boundary stricter for the blend than for either single vial. Keep these limits in view:
- Avoid recovery, injury, pain, tendon, or healing promises in product-facing copy.
- Do not frame the blend as "more effective" than separate vials — no controlled human data supports that.
- Do not use the word "synergy"; the published basis is complementary co-administration only.
- Do not give protocol, administration, or human-use instructions; use COA and supplier-verification language instead of outcome language.
Our Research Standards
This guide draws on the existing BPC-157 and TB-500 component guides, the dual-peptide mechanism review, live product-catalog data, and peer-reviewed and official sources, including PubMed and ClinicalTrials.gov searches that confirm the absence of any human combination trial. No therapeutic, human-use, or veterinary-use claim is made. Read our editorial policy →
BPC-157 + TB-500 Blend Research FAQ
Can Dubai researchers buy the BPC-157 + TB-500 blend from Remy Peptides?
Yes. Remy Peptides lists the BPC-157 + TB-500 blend vial as in stock for research-use-only orders in Dubai and the UAE. The live product page is the source of truth for current stock, AED pricing, and COA request details.
What is the format of the BPC-157 + TB-500 blend vial?
The blend is a single lyophilized research vial containing 5 mg BPC-157 co-formulated with 5 mg of the TB-500 synthetic Thymosin Beta-4 fragment, for 10 mg total peptide content at a fixed 1:1 mass ratio. Current AED price tiers start around AED 500 in the catalog, but prices and orderability can change, so the product page should be checked before any research order.
How is the COA and purity verified for a two-peptide blend vial?
A blend Certificate of Analysis confirms both components separately: mass-spectrometry identity for BPC-157 (CAS 137525-51-0) and the TB-500 fragment (Tβ4 reference CAS 77591-33-4), plus HPLC purity for each peptide and the 5 mg + 5 mg fill. Check the product page and COA library, or request the lot-specific HPLC documentation when a public batch file is not yet posted.
Is the BPC-157 + TB-500 blend sold for human or veterinary use?
No. Remy Peptides products are supplied strictly for in-vitro laboratory research. They are not for human use, veterinary use, diagnosis, treatment, cure, disease management, or personal-use protocols. There are no peer-reviewed human trials of the BPC-157 + TB-500 combination.
Should researchers choose the blend or the separate BPC-157 and TB-500 vials?
The blend is a co-formulation convenience that fixes the ratio at 1:1 by mass and removes the per-compound dilution step, which suits fixed-ratio in-vitro work. Investigators who need independent dose control, different per-compound reconstitution volumes, or per-compound COA tracking should use the separate BPC-157 10mg research vial and TB-500 10mg research vial instead.
Sources
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. PMID: 40789979. Mechanism depth in the dedicated BPC-157 guide. ↑
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005. PMID: 16099219. Component detail in the dedicated TB-500 guide. ↑
- Lee E, Burgess K. First-in-human intravenous pilot administration of BPC-157 in healthy adults: a two-subject safety report. 2025. PMID: 40131143. A PubMed and ClinicalTrials.gov search at the time of writing returns no peer-reviewed human trial of the BPC-157 + TB-500 combination; see the dual-peptide mechanism review for the full evidence-gap discussion. ↑
For current stock, pricing, and COA route, use the live BPC-157 + TB-500 blend vial page. For component detail, see the BPC-157 Dubai guide and TB-500 Dubai guide. For wider supplier verification, continue to the peptide COA guide and official contact verification.